EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

 
• By Neena Brizmohun

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.

Review document
Some new treatments will move closer to approval • Source: Shutterstock

More from Europe

More from Geography